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ABSTRACT 
 
The RTGene study was focused on the development and validation of new transcriptional 
biomarkers for prediction of individual radiotherapy patient responses to ionising radiation. 
In parallel, for validation purposes, the study has incorporated conventional biomarkers of 
radiation exposure, including the dicentric assay. Peripheral blood samples were taken with 
ethical approval and informed consent from a total of 20 patients undergoing external beam 
RT for breast, lung, gastrointestinal or genitourinary tumours. For the dicentric assay, two 
samples were taken from each patient: prior to radiotherapy and before the last fraction. 
Blood samples were set up using standard methods for the dicentric assay. All the baseline 
samples have dicentric frequencies consistent with the expected background for the normal 
population. For blood taken before the final fraction, all the samples display distributions of 
aberrations which are indicative of partial body exposures. Whole body and partial body 
cytogenetic doses were calculated with reference to a 250 kVp X-ray calibration curve and 
then compared to the dose to blood derived using two newly developed blood dosimetric 
models. Initial comparisons indicate the relationship between these measures of dose looks 
very promising, with a correlation of 0.88 (p = 0.001). A new Bayesian zero-inflated Poisson 
finite mixture method has been applied to the dicentric data and partial body dose 
estimates show no significant difference (p > 0.999) with those calculated by the 
contaminated Poisson technique. The next step will be further development and validation 
in a larger patient group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Background to the RTGene Project  
Biological markers of radiation exposure play a crucial role in the triage of suspected 
exposed persons following a radiation accident or incident (1, 2). In recent years the gene 
expression assay has been shown to be a sensitive marker of radiation exposure, with the 
potential to be used for truly individualised biological dosimetry (3, 4, 5). Classic cytogenetic 
techniques, and in particular the gold standard dicentric assay, have two main 
disadvantages in mass casualty scenarios: (1) lack of high-throughput and (2) delays of 
several days between blood sampling and the availability of results (1). Using blood samples, 
gene expression analysis can provide valuable information, as there is a window of time (i.e. 
12-48 hours) following radiation exposure where specific radiation-responsive genes have 
linear dose responses (0-5 Gy) (5). New technology for gene expression analysis allows 
direct counting of nucleic acid molecules (DNA, mRNA, miRNA and lncRNA) without the 
need for enzymatic reaction or amplification steps hence reducing time for data collection 
(6) and has been assessed for radiation biodosimetry applications with promising results (7). 
Linearity of the transcriptional dose-response for specific radiation-responsive genes in ex 
vivo exposed human blood samples has recently been demonstrated for the first time, and 
inter-individual variability in the response after low doses and high doses exposures has 
been newly assessed (3, 5). The logical next stage for biological development of the gene 
expression assay was to further validate these new techniques with human blood samples 
exposed to radiation in vivo (8, 9). The RTGene Project was a feasibility study to develop 
existing knowledge on coding and non-coding transcriptional responses to ionising radiation 
(IR) into a useable radiation specific biomarker of exposure and response using blood 
samples from radiotherapy (RT) patients. In parallel, for validation purposes, the study 
included conventional biomarkers of radiation exposure, i.e. chromosome aberrations using 
the dicentric assay (DCA) and DNA damage using the gamma-H2AX foci assay. 
 
A range of standard RT schedules was chosen for inclusion in this study to provide a wide 
range of doses for assessment of the gene expression assay alone and in combination with 
the DCA, to simulate a wide range of potential exposure scenarios. Conventional 
cytogenetics was chosen for inclusion in the RTGene project, because the DCA is the most 
widely used and validated biological dosimetry assay, as well as being a standardised 
technique (1, 10). Whole body (WB) and partial body (PB) doses can be assessed based on 
the observed yield of dicentric chromosome aberrations with reference to an appropriate 
calibration curve (1). Not only can cytogenetic dose estimates be used to validate the gene 
expression assay, but they can be compared to the calculated dose to blood during RT from 
dosimetric models. In addition, the DCA data can be applied to a more sophisticated 
Bayesian zero-inflated Poisson finite mixture method to calculate PB dose estimates and 
then compared to the RT data.  
 
Blood dosimetric models  
Radiotherapy treatment planning systems produce detailed maps of the predicted radiation 
dose to be delivered by the treatment units. The radiation dose is focussed on an area 
outlined on a computed tomography (CT) image set by a radiation oncologist. This region is 
referred to as the target volume and is the site of the primary tumour, tumour bed or region 
to which the cancer has spread. Radiotherapy is most commonly delivered using photon 
radiation. Photon radiation is attenuated, but not stopped, by the body hence non-target 
normal tissues in the path of the beam receive radiation dose. Non-target tissues/organs of 
particular concern in the vicinity of the target volume are also outlined by the radiation 
oncologist so that the radiation dose received by them is minimised in the planning process. 
Radiotherapy dose information whilst reasonably accurate in the target volume, (11), 
provides information only on static objects which have been explicitly delineated in the 
treatment planning system. It can be used to infer dose to the circulating blood but does not 
give this directly. For this reason, two simple models were set up to test for correlation with 
the dicentric dose models.  
 
The Bayesian zero-inflated Poisson finite mixture method to assess partial body exposure 
IR produces damage at a cellular level in humans and as mentioned before, the DCA is a 
well-established cytogenetic biomarker of radiation exposure. To calibrate the effect of IR, 
dose-response curves are built, by the irradiation of in vitro blood samples to different 
doses, simulating homogeneous whole body exposure. For this kind of exposure, it is 
typically assumed that the yield of dicentrics per blood cell is a Poisson number whose 
intensity is a quadratic function of the dose, 𝛽0 + 𝛽1𝐷 + 𝛽2𝐷
2 (for more details, see 1). 
Gradient exposures are heterogeneous irradiations where different doses occur in the 
irradiation field within the individual's body. PB irradiations are those where the dose or 
doses are not absorbed by the whole body of the individual, i.e. there is a fraction of the 
body which is non-irradiated. Traditionally, an estimate of PB dose has been estimated by 
using, for example, the contaminated Poisson method (12), but more recently a Bayesian 
zero-inflated Poisson finite mixture model has been applied to cytogenetic data derived 
from simulated PB exposures (13). 
This paper looks at the dicentric dose estimates for patients undergoing radiotherapy 
enrolled in the RTGene study to assess 1) blood dosimetric models and 2) the Bayesian zero-
inflated Poisson finite mixture method for estimating partial body exposure. Additional 
results from gene expression, radiation induced gamma-H2AX foci and translocation 
analysis, plus a comparison of the cytogenetic dose estimates with the gene expression data 
will be the subject of separate papers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
Patient selection and blood sampling 
Eligible volunteers who required external beam RT for breast, lung, gastrointestinal or 
genitourinary tumours were identified in the Outpatient Department at The Royal Marsden 
NHS Foundation Trust (RM). Patients were included in the study if: a) they were aged 18 
years or older; b) had no previous RT; c) not concurrently receiving chemotherapy or not 
less than four weeks before RT; d) not concurrently receiving hormone therapy or not less 
than four weeks before RT; e) written informed consent was given, but could be withdrawn 
at any time. The study was carried out in accordance with the Declaration of Helsinki (1964), 
the Research Governance Framework 2nd edition (2005) and the Human Tissue Act (2004). 
The study was approved by the South Central-Hampshire B Research Ethics Committee 
(16/SC/0307) and registered with ClinicalTrials.gov (NCT02780375). All relevant information 
was collected from the participants and extracted from their case notes by the research 
team at RM and only transferred to Public Health England (PHE) for the final analysis. No 
identifiable information was passed between the two institutions and patient confidentiality 
was maintained at all times. Heparinized venous blood was collected from a total of 20 
volunteers, prior to RT and before the last fraction for the DCA. Coded samples were 
dispatched by express courier overnight to PHE. The 20 volunteers were made up of 
patients undergoing RT treatment for the following tumour types: breast (5 patients); 
endometrial (4 patients); prostate (3 patients); lung (5 patients); oesophageal (2 patients) 
and colon (1 patient). The RT schedules and doses are shown in Table 1 for each of the 20 
volunteers. Also included in Table 1 is the 95% isodose volume for each patient, to give an 
indication of the different sizes of the field irradiated. 
 <Table 1> 
RTGene ID 
RT treatment 
to 
RT 
prescribed 
target dose 
(Gy) 
Number of 
RT fractions 
RT 
prescribed 
target dose 
per fraction 
(Gy) 
95% iso 
dose 
volume 
(cm3) 
RTG002 Breast (right) 40.05 15 2.67 726 
RTG003 Endometrium 45 25 1.80 1779 
RTG004 Breast (left) 40.05 15 2.67 954 
RTG005 Breast (left) 40.05 15 2.67 734 
RTG006 Breast (right) 40.05 15 2.67 1044 
RTG007 Endometrium 45 25 1.80 1362 
RTG008 Prostate 60 20 3.00 89 
RTG009 Lung 55 20 2.75 520 
RTG010 Lung 55 20 2.75 281 
RTG011 Prostate 60 20 3.00 202 
RTG012 Lung 55 20 2.75 624 
RTG013 Lung 55 20 2.75 415 
RTG014 Lung 55 20 2.75 927 
RTG015 Endometrium 45 25 1.80 1469 
RTG016 Endometrium 45 25 1.80 1134 
RTG017 Prostate 60 20 3.00 123 
RTG018 Oesophagus 36 12 3.00 1152 
RTG019 Breast (both) 40.05 15 2.67 1729 
RTG020 Oesophagus 20 5 4.00 2197 
RTG021 Colon 40 15 2.67 599 
 
Table 1. Table showing the tumour type, the RT schedule and the RT prescribed doses, 
together with the 95% isodose volume for each patient. 
 
 
Dicentric assay 
On arrival at the laboratory whole blood was mixed with Minimal Essential Medium (MEM) 
for the DCA (Sigma-Aldrich, Dorset, UK), supplemented with 10% heat-inactivated foetal 
bovine serum, 1% phytohaemagglutinin, 100 units/ml penicillin plus 100µg/ml streptomycin 
2mM L-glutamine (all from Invitrogen, Paisley, UK). In addition, 5-bromo-2-deoxyuridine 
(Sigma-Aldrich, Dorset, UK) was added to the DCA cultures at a final concentration of 10 
µg/ml. All samples were cultured at 37 °C in a 5% CO2 humidified atmosphere. After 45 
hours (h) Colcemid (Sigma-Aldrich, Dorset, UK) was added to each culture to give a final 
concentration of 0.2 µg/ml. At 50 h metaphases were harvested by a standard hypotonic 
treatment in 0.075 M potassium chloride for 7 min at 37°C followed by three changes of 3:1 
methanol:acetic acid fixative. Fixed cells were dropped onto clean microscope slides, air 
dried and stained using the fluorescence plus Giemsa technique. The culture, fixation and 
staining procedures followed the standard protocol recommended by the International 
Atomic Energy Agency (1). A maximum of 1000 first division metaphases per donor for the 
pre-RT sample and 500 cells or 100 dicentrics for the final sample were scored manually for 
chromosome aberrations.  Dose estimates, based on the number of dicentrics per cell were 
calculated using Dose Estimate_v5.1 (14) and PHEs standard 250 kVp X-ray calibration curve, 
with following coefficients C = 0.0005 ± 0.0005, α = 0.046 ± 0.005, β = 0.065 ± 0.003 (15). In 
addition, the standard ‘contaminated Poisson’ method to calculate the most likely partial 
body dose, % of lymphocytes exposed and % of the body exposed was applied (1). 
 
 
 
 
Simple blood dosimetry models 
The first model, Model 1 (EDD1) uses typical values for the circulation time of blood in 
humans combined with the time taken for radiotherapy to be delivered. It uses the high 
dose (volume within 95% isodose curve on the radiotherapy treatment plan) as a fraction of 
an assumed 6 litres of blood for a human with a blood flow rate of 6 litres a minute. A RT 
irradiation time of 1 minute is assumed: 
 
DB  = dose to blood per fraction =  DF  × (V95%  ÷  VB) (Gy),  (3) 
 
where V95% = high dose volume which is specific to each patient (cc); VB = total blood 
volume, assumed to be 6 litres; DF = radiotherapy dose per fraction which is specific to each 
patient (Gy). The main limitations of model 1 are a lack of patient specific blood volume, 
circulation time and no knowledge of volumes of blood in different organs. The uncertainty 
of V95% is of the order of 2% – 3%; that of VB is of the order of 20%; DF is a set number (the 
specified dose prescription) and as such does not have an uncertainty; the blood flow rate 
and RT irradiation times will have variation of at least 20%. It is likely that DB calculated 
using this method will have a minimum uncertainty of at least 20%. 
 
The second model, Model 2 (EDD2), uses patient specific data. Model 2 estimates a whole 
body mean dose and assumes the blood receives this.  The whole body dose is calculated 
using the mean dose for the volume of the body covered by the CT planning scan.  This is 
scaled assuming the total body volume is 2.5 times this volume: 
 
DB  = dose to blood per fraction = (DPB ÷ DF)  × 2.5 (Gy),  (4) 
 
where DPB = mean dose (Gy) of body volume covered by CT scan (specific to each patient); 
DF = RT dose (Gy) per fraction which is specific to each patient. The main limitations of 
model 2 are the use of an estimate of 2.5 for the scaling factor from partial to whole body 
volume and a lack of knowledge of the amount of blood volume in specific organs. The 
uncertainty of DPB is of the order of 2% – 3%; DF is a set parameter and as such there is no 
uncertainty associated with it; the factor 2.5 is estimated to have an uncertainty of 30% - 
40%. It is likely that DB calculated using this method will have an uncertainty of around 40%. 
It is non-trivial to determine the volume of blood and blood flow through specific organs 
relevant to RT and similarly, partial body dose (EDD2) without whole body imaging 
information. Investigations are underway into more sophisticated estimates using virtual 
body phantoms. 
 
Bayesian zero-inflated Poisson finite mixture method 
The goal is to estimate the absorbed doses and the irradiated fractions for each irradiated 
component. In a scenario of partial body gradient exposure with 𝑘 irradiated components, 
given a sample 𝑦 = {𝑦1, … , 𝑦𝑛} of 𝑛 chromosomal aberration counts within blood cells, the 
yield of chromosomal aberrations can be represented by a zero-inflated Poisson finite 
mixture model whose probability mass function has the form 
𝑝(𝑦𝑖|𝜔, 𝜆) = 𝜔01(𝑦𝑖=0) + ∑ 𝜔𝑗
𝑘
𝑗=1 𝑝(𝑦𝑖|𝜆𝑗),      (1)            
where 𝜔 denotes the proportions (with ∑ 𝜔𝑗
𝑘
𝑗=0 = 1), 𝜆 is the vector of Poisson intensities, 
𝑝(𝑦𝑖|𝜆𝑗) = 𝑒
−𝜆 𝜆𝑦𝑖 𝑦𝑖!⁄  is the Poisson probability of observing 𝑦𝑖 for expectation 𝜆𝑗(> 0), 𝑖 
is the index of observations, and 1(𝑦𝑖=0) takes the value 1 if 𝑦𝑖 = 0 and 0 otherwise. Values 
𝜆𝑗 and 𝜔𝑗 represent the yield of chromosomal aberrations and the proportion of scored cells 
at component 𝑗 respectively. Value 𝜔0 is the proportion of extra zeroes, over and above 
those expected from a purely Poisson process, and represents the proportion of non-
irradiated scored cells. 
The doses for each component, 𝐷𝑗 , are estimated by matching the yield of aberrations to 
the fitted dose-response curve, 𝛽0 + 𝛽1𝐷𝑗 + 𝛽2𝐷𝑗
2 = 𝜆𝑗. To calculate the number of 
irradiated fractions within the body, 𝐹𝑗, it is necessary to rescale the proportion of scored 
cells by adding to each component the proportion of cells which died because of the 
irradiation, i.e. 
𝐹0 =
𝜔0
𝜔0+∑ 𝜔𝑙𝑒
𝐷𝑙 𝑑0⁄𝑘
𝑙=1
, 𝐹𝑗 =
𝜔𝑗𝑒
𝐷𝑗 𝑑0⁄
𝜔0+∑ 𝜔𝑙𝑒
𝐷𝑙 𝑑0⁄𝑘
𝑙=1
, (2) 
where 𝑑0is the 37% cell survival dose, with experimental evidence to be between 2.7 and 
3.5 Gy (1). 𝐹0 represents the fraction of the body non-irradiated and 𝐹𝑗  represents the 
fraction of the body irradiated by dose 𝐷𝑗 . 
A Bayesian model is proposed to estimate both the doses and the fractions, assuming prior 
distribution densities for each of the parameters. The technique proposed here consists of 
two steps. The first step is to infer the yields and the proportions and the second is to get 
the estimation of the doses and the fractions using formulas 1 and 2 (shown above).  
Given a sample 𝑦 and assuming the observations are independent, the likelihood is the 
product of the probability of the observations, 𝐿(𝜔, 𝜆|𝑦𝑖) = ∏ 𝑝(𝑦𝑖|𝜔, 𝜆)
𝑛
𝑖=1 . Assuming 𝜔 
and all 𝜆𝑗 values are independent the following prior structure is defined as: 
𝜔~Dirichlet(1⃗ 𝑘+1), (5) 
𝜆𝑗~𝒰(0,𝑀), 𝜆𝑗+1 > 𝜆𝑗 , 𝑀 = max(𝑦), (6) 
The prior for the proportions of scored cells, 𝜔, is a flat Dirichlet distribution of 𝑘 +
1elements. The ordering constraint of the yields prior is to ensure identifiability. By the 
Bayes' theorem, the joint posterior distribution of {𝜔, 𝜆} is 
𝑝(𝜔, 𝜆|𝑦𝑖) =
𝐿(𝜔,𝜆|𝑦𝑖) 𝑝(𝜔,𝜆)
∫ 𝐿(𝜔,𝜆|𝑦𝑖) 𝑝(𝜔,𝜆) 𝑑𝜔 𝑑𝜆
, (7) 
where 𝑝(𝜔, 𝜆) is the product of the prior densities of all 𝜆𝑗 and 𝜔. The above joint posterior 
density has a non-tractable form, so acceptance-rejection sampling is used to simulate it. 
Let ?̂? be the maximum value of 𝐿(𝜔, 𝜆|𝑦𝑖), then the next steps sample the joint posterior 
distribution by: 
1. Generate 𝑢 from 𝒰(0,𝑀). 
2. Generate one random variate for each prior, 𝜔∗ and 𝜆∗, all them independent of 𝑢. 
3. Compute 𝐿∗ = 𝐿(𝜔∗, 𝜆∗|𝑦𝑖). If 𝑢 < ?̂? 𝐿
∗⁄ , then set {𝜔∗, 𝜆∗} to the joint posterior 
sampling.  
4. When the size of the sample is lower than the desired value, go to step 1. 
To get the joint posterior distribution of the doses and the fractions, a prior is defined for 
the calibration coefficients {𝛽0, 𝛽1, 𝛽2}, based on the dose-response curve maximum 
likelihood estimation. Another prior is defined for the cell survival dose, which is uniform 
between 2.7 and 3.5 Gy. Keeping independency for all priors, the additional prior structure 
is defined as: 
𝛽~𝑁(?̂?, Σ̂), 
𝑑0~𝒰(2.7,3.5), 
Hence, the following steps are included in the previous algorithm after step 3 if the 
condition is met: 
a) Generate one random variable for the new priors: 𝛽∗ and 𝑑0
∗ . 
b) Calculate a new sample for the doses by solving  𝛽0 + 𝛽1𝐷𝑗
∗ + 𝛽2𝐷𝑗
∗2 = 𝜆𝑗
∗. 
c) Calculate the fractions from  
𝐹0
∗ =
𝜔0
∗
𝜔0
∗+∑ 𝜔𝑙
∗𝑒𝐷𝑙
∗ 𝑑0
∗⁄𝑘
𝑙=1
, 𝐹𝑗
∗ =
𝜔𝑙
∗𝑒
𝐷𝑗
∗ 𝑑0
∗⁄
𝜔0
∗+∑ 𝜔𝑙
∗𝑒𝐷𝑙
∗ 𝑑0
∗⁄𝑘
𝑙=1
.,  (8) 
After this process, samples {𝐹, 𝐷} represent the joint posterior densities and the posterior 
marginal densities and are represented by each 𝐹𝑗 or 𝐷𝑗  for the joint sample. 
 
This method was applied to the dicentric data to estimate PB doses assuming 2, 3, 4, 5 and 6 
irradiated fractions. Due to computational intensity, the number of simulated draws of the 
joint posterior densities is decreased as the assumption of the number of irradiated 
components increases. The simulation size for each scenario was as follows: 10000 for 2; 
1000 for 3, 4 and 5; 100 for 6 irradiated fractions. The Bayesian Information Criterion (BIC) 
value was also calculated for the different scenarios.  
 
 
 
Other data analysis 
The distribution of dicentric aberrations among the scored cells for each sample was tested 
for conformity with the Poisson distribution by calculating the dispersion index (the ratio of 
variance to mean) using Dose Estimate_v 5.1 software (14). Over dispersion being indicated 
by a value > 1.0 and hence pointing to a PB irradiation (1). In order to investigate whether 
there was a statistically significant difference in dose response with cancer type, general 
linear model analysis of variance (GLM ANOVA) was carried out, with post-hoc testing using 
Tukey’s pairwise comparisons within factors, using Minitab® 17. For comparison of the 
Bayesian and standard PB method, the doses calculated by each technique were normalised 
and compared using the standard Student’s t-test. 
 
 
 
RESULTS 
 
All baseline samples have dicentric frequencies consistent with the expected background for 
the normal population (0 – 2 in 1000); with no cell containing more than 1 dicentric.  The 
dicentric distributions for all the samples, pre RT and prior to the final fraction, were tested 
for conformity to the Poisson distribution. As expected, there is no indication of departure 
from the Poisson distribution, so there is no evidence of recent whole or partial body 
exposures, in the pre RT treatment samples.  For the samples taken prior to the final 
fraction, all samples display distributions of aberrations which are indicative of partial body 
exposures to some degree, as illustrated in Table 2. 
 
<Table 2> 
 
Table 2. Dicentric chromosome aberrations in samples taken prior to the final RT fraction. 
Cells = Number of peripheral blood lymphocytes scored; Dics = Number of dicentric 
chromosome aberrations identified; y = yield of dicentrics; var:mean = variance: mean ratio, 
an indication of departure from Poisson and thus partial body exposure (var:mean for 
Poisson = 1); SE = standard error of the measurement in the previous column. In all the pre 
RT samples no cell contained more than 1 dicentric, thus the var:mean = 1.0 in all cases. 
RTGene ID 
Pre RT treatment sample Sample taken prior to the final RT fraction 
Cells Dics Cells Dics Y SE var:mean SE 
RTG002 1000 1 500 20 0.040 0.009 1.360 0.062 
RTG003 1000 2 171 99 0.579 0.058 1.790 0.108 
RTG004 1000 1 500 19 0.038 0.009 1.390 0.062 
RTG005 1000 2 500 23 0.460 0.010 1.300 0.062 
RTG006 1000 0 500 19 0.038 0.009 1.070 0.062 
RTG007 1000 0 233 100 0.429 0.043 1.100 0.092 
RTG008 1000 1 500 36 0.072 0.012 1.150 0.062 
RTG009 919 1 202 100 0.500 0.050 2.280 0.099 
RTG010 514 1 488 101 0.207 0.039 1.990 0.064 
RTG011 1000 2 500 60 0.120 0.028 1.350 0.063 
RTG012 1000 0 203 100 0.493 0.091 2.020 0.099 
RTG013 1000 1 309 100 0.323 0.059 1.660 0.080 
RTG014 1000 2 132 103 0.780 0.143 1.830 0.123 
RTG015 1000 0 181 100 0.552 0.102 2.080 0.105 
RTG016 1000 1 264 100 0.379 0.070 1.270 0.087 
RTG017 1000 1 500 90 0.180 0.035 1.820 0.063 
RTG018 1000 2 181 100 0.552 0.102 1.680 0.105 
RTG019 1000 1 500 91 0.182 0.035 1.680 0.063 
RTG020 1000 1 500 99 0.198 0.037 3.010 0.063 
RTG021 1000 0 276 100 0.362 0.050 1.720 0.085 
 
 
The BIC values for the different exposure scenarios, assuming PB irradiation, were 
calculated (data not shown). Lower BIC values indicate a better fit. Following this criterion, a 
PB irradiation with 2 irradiated components was the best fit for the dicentric data for all 
patients. The results of the cytogenetic dose estimates (standard and Bayesian methods) 
and dose to blood calculated from the two models are given in Table 3.  
 
<Table 3>  
 
Table 3. Dose following the penultimate fraction for each participant calculated using blood 
dosimetric models and the cytogenetic dose estimates calculated by standard and Bayesian 
methods (95% HPDCI = 95% Highest Posterior Density Credible Interval) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
EDD1   
(Gy)
EDD2   
(Gy)
Dose    
(Gy)
SE
Dose    
(Gy)
SE
% Cells 
irradiated
% Body 
irradiated
% Body 
not 
irradiated
Dose 1 
(Gy)
95% HPDCI
Fraction 1 
(%)
Dose 2 
(Gy)
95% HPDCI
Fraction 2 
(%)
RTG002 2.26 1.08 0.50 0.08 2.34 0.42 8.6 18.3 67.7 1.28 0.00 - 2.77 21.5 2.96 1.45 - 4.89 10.7
RTG003 12.81 5.49 2.65 0.16 4.01 0.84 47.1 79.7 17.9 2.87 0.94 - 4.39 42.9 5.23 3.56 - 7.85 39.1
RTG004 5.94 1.26 0.48 0.08 2.01 0.38 10.7 20.2 58.8 1.04 0.01 - 2.32 32.1 3.27 1.17 - 6.05 9.2
RTG005 4.57 1.28 0.56 0.08 2.14 0.39 11.6 22.5 63.1 1.22 0.001 - 2.57 24.4 2.78 1.14 - 4.62 12.5
RTG006 6.50 1.64 0.48 0.08 0.99 0.24 34.5 43.3 45.9 0.78 0.002 - 1.65 36.7 1.91 0.51 - 4.15 17.5
RTG007 9.81 4.30 2.24 0.14 2.50 0.57 82.5 92.3 8.3 2.14 1.01 - 3.08 49.5 3.24 2.23 - 5.09 42.1
RTG008 0.85 1.75 0.75 0.01 1.60 0.33 29.9 43.6 42.8 1.07 0.03 - 2.02 36.4 2.28 0.97 - 4.25 20.8
RTG009 4.53 3.19 2.43 0.15 4.53 0.86 32.1 71.7 26.8 3.12 0.88 - 4.82 37.1 5.95 4.14 - 8.44 36.1
RTG010 2.45 1.77 1.46 0.09 3.36 0.53 23.4 51.4 41.2 2.35 0.99 - 3.35 45.5 6.48 3.90 - 9.18 13.4
RTG011 1.92 1.98 1.05 0.09 2.34 0.42 25.9 45.4 43.9 1.48 0.18 - 2.72 34.1 3.11 1.75 - 5.11 22.0
RTG012 2.26 3.17 2.42 0.15 3.90 0.78 42.2 75.6 12.3 2.14 1.24 - 3.25 53.7 5.99 4.25 - 7.69 34.1
RTG013 0.91 2.35 1.90 0.12 3.16 0.60 40.7 68.9 17.2 1.89 1.02 - 3.04 57.8 5.05 3.07 - 6.99 25.0
RTG014 5.11 3.00 3.13 0.18 4.33 0.96 55.0 85.9 11.3 2.94 1.30 - 4.59 42.4 5.54 4.05 - 7.49 46.3
RTG015 4.06 4.80 2.58 0.06 4.21 0.85 41.1 76.8 18.3 2.78 1.29 - 4.24 47.0 6.09 4.11 - 8.27 34.8
RTG016 5.33 4.94 2.08 0.13 2.65 0.57 65.6 83.6 12.5 2.06 0.87 - 3.03 53.7 3.80 2.26 - 6.36 33.8
RTG017 0.38 1.78 1.35 0.09 2.68 0.46 30.5 54.2 36.6 2.12 1.38 - 2.82 56.6 8.48 5.16 - 10.85 6.8
RTG018 3.56 1.95 2.58 0.06 3.60 0.78 54.8 82.1 13.0 2.66 1.43 - 3.85 57.4 5.68 3.37 - 8.51 29.6
RTG019 10.77 2.58 1.35 0.09 3.22 0.51 22.1 48.3 45.0 2.02 0.28 - 3.53 30.0 4.03 2.68 - 5.92 25.0
RTG020 7.32 1.08* 1.43 0.09 4.82 0.66 11.4 43.5 45.4 1.98 0.51 - 3.59 29.4 6.67 5.31 - 8.26 25.2
RTG021 3.73 2.14 2.03 0.10 3.60 0.67 35.9 68.0 27.4 2.35 0.62 - 3.94 37.0 4.54 3.13 - 6.59 35.7
95% HPDCI = 95% Highest Posterior Density Credible Interval
RTGene 
ID
Blood model doses                         
Blood cytogenetic dose estimates 
Whole body Partial body Bayesian partial body assuming 2 irradiated fractions (mean values)
Figure 1 compares the doses to blood during RT calculated using ICR/Royal Marsden 
(ICR/RM) blood dose models 1 (EDD1) and 2 (EDD2) and the dicentric doses, estimated using 
Dose Estimate_v5.1 and the standard contaminated Poisson method, to the WB and PB. As 
illustrated, the relationship between WB dose and EDD2 gives a regression coefficient (± 
standard error) of 0.607 (± 0.029), with an R^2 value of 0.88 and 95% confidence limits (CLs) 
0f 0.84 – 0.94. The corresponding values for PB dose and EDD2 are 1.010 (± 0.079) and 0.72 
(95% CLs 0.60 – 0.84) respectively. An F-test p-value of 0.001 for the significance of the 
relationships and the 95% CLs indicate no substantial overlap. For EDD1, there was no 
significant linear relationship between the model dose and either WB or PB dose, but the 
R^2 correlations for the plotted relationships were 0.04 and 0.03, respectively. As the 
models were only initial indications, equal weighting of each point was applied in this case.  
 
<Figure 1>  
 
Figure 1. Dose following the penultimate fraction to blood during RT calculated using 
models 1 (EDD1) and 2 (EDD2) and cytogenetic doses to the WB and PB, calculated using the 
standard contaminated Poisson methodology to separate exposed and unexposed fractions 
in PB exposures. 
 
PB dose estimates calculated by the standard contaminated Poisson method and the new 
Bayesian technique were compared using the average body doses. These were calculated as 
the product of the irradiated fraction and dose for the standard method and the sum of the 
product of the respective doses and fractions for the Bayesian technique. A Student’s t-test 
on these normalised values showed no significant difference (p > 0.999) between doses 
calculated by the Bayesian and the standard method.  
 
Grouping the results in Table 3 by cancer type, in order to investigate whether there is a 
difference in dose response, calculated using standard methods for the dicentric data, then 
applying GLM ANOVA for this factor with post hoc testing, showed the type of cancer had a 
significant effect on the WB and PB dose (p < 0.001). The ANOVA comparisons revealed that 
RT treatment for some cancer types resulted in either significantly lower or higher WB or PB 
doses and these are presented in Table 4. No other significant differences were observed. 
 
<Table 4.> 
 Table 4. Table showing GLM ANOVA comparisons that revealed RT treatment for some 
cancer types resulted in either significantly lower (*) or higher (†) WB or PB cytogenetic 
doses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endometrial Lung Oesophageal Colon Prostate 
Breast* p < 0.001 p < 0.001 p < 0.001 ns ns
Prostate*  p < 0.001 p < 0.001 ns p = 0.026
Breast* ns p = 0.005 p = 0.013 ns ns
Lung† ns ns ns ns p = 0.029
Oesophageal†   ns ns ns ns p = 0.037
ns = not significant
Cancer type: Calculated 
dose
whole body
partial body
* calculated dose significantly lower than for the other cancer types shown
† calculated dose significantly higer than for the other cancer types shown
DISCUSSION 
 
Biomarkers of radiation exposure have been used for biological dose estimation for many 
years; in particular the DCA has been in use since the mid-1960s (1). Biodosimetry methods 
have the potential to contribute to epidemiological studies of ionising radiation effects (16, 
17, 18). With the aim to improve the application of RT, the significance of predictive and 
prognostic biomarkers of response to radiation has also been demonstrated (19, 20, 21). In 
addition, some studies using cytogenetic biodosimetry assays have shown they may be 
considered as a predictor of radiosensitivity to identify patients likely to develop acute / 
chronic adverse effects from RT (22, 23, 24), although these studies have been small in scale 
and not prospectively validated. Gene expression analysis has shown possible potential as a 
marker of radiosensitivity (25, 26, 27) and as a sensitive biological marker for biological 
dosimetry (3, 5, 28, 29). Despite modern techniques the DCA remains the most specific and 
standardised method for biological dosimetry (30) and hence it is the assay best suited to 
validate the gene expression technique for dose estimation. 
 
RTGene was a feasibility study to develop and further validate the gene expression assay for 
biodosimetry with human blood samples exposed in vivo (8, 9) and included conventional 
biomarkers for additional validation. This has allowed dose estimates based on the dicentric 
assay to be calculated. As Table 1 shows, the RT schedules and doses for the patients are 
different and the results of the AVOVA analysis indicate cancer site has a significant effect 
on the WB and PB dicentric dose estimates. When the cancer sites were compared further, 
significant differences were observed, with treatment for breast and prostate cancer 
resulting in significantly lower cytogenetic dose estimates than other groups. With breast 
and prostate RT the high dose volumes are generally smaller than those in other tumour 
sites resulting in lower WB and PB doses. Breast in particular, if treated with tangential 
fields only (as is the case in this study), spares the lung and heart, with most of the dose 
going through less vascular tissue within the breast. Lung and oesophagus RT would 
invariably result in doses to highly vascular organs such as lung and heart and this is 
reflected in the DCA and blood dosimetric models applied here.  
 
To the authors knowledge there are currently no recommended published methods to 
calculate the dose to circulating blood for RT. EDD1 and EDD2 are relatively simple blood 
dosimetry models, but the assumptions contained in the models are close to reality. The 
blood volume of an adult is considered to be around 6 litres, although this varies from 
individual to individual. The irradiation time for the model of 1 minute was a typical value, 
as RT is planned to the requirements of each individual and the time will be depend on 
these factors, the prescribed dose, the dose rate which the treatment machine can deliver 
and the type of delivery (static or rotating). It is difficult to give a range of irradiation times 
that encompasses all possibilities however appropriate values for the patients in the 
RTGene study are between 30 to 120 seconds. Modelling dose to blood during RT is a 
relatively small field, but the recent publication (31) modelled dose to circulating 
lymphocytes for patients receiving RT for malignant gliomas. A similar approach was taken 
to the models described here in that assumptions were made about blood flow and blood 
volume in the body, for example. The results in (31) indicate that after the total course of RT 
most of the blood received > 0.5 Gy, results which are supported by the two simple models 
(EDD1 and EDD2) and even the dicentric dose estimates in this study. However, the difficulty 
of not having whole body, and specifically accurate whole blood volumes, means both (31) 
and the current work have limitations that are clearly acknowledged. 
 
Dicentric doses, estimated using standard methods (1), have been compared to the 
calculated dose to blood derived using two newly developed ICR/RM dosimetric models. 
Dicentric chromosome aberrations are the result of mis-repair of DNA double strand breaks 
induced by ionising radiation (1) with most being formed quickly, within 2 hours of 
irradiation (32). The DCA evaluates damage in PHA responsive T-lymphocytes, 
predominantly the CD4+ and CD8+ sub-types. There are large uncertainties on the lifespan of 
lymphocytes however, chromosomal damage following radiotherapy in CD4+ and CD8+ 
lymphocytes, which express naïve/memory markers (CD45RA+/RO+), has been studied. 
CD45RA+ cells have been shown to divide every 3.5 years and those expressing CD45RO+ 
every 22 weeks, on average (33). Generally, it is thought that approximately 80% of 
circulating lymphocytes survive for about 4 years (34, 35) and the biological half-life of 
dicentric chromosomes is about 3 years (36), albeit with some uncertainty. The patients in 
the RTGene study received RT over a period of 7 to 37 days, before the post RT blood 
sample was taken, therefore the repopulation of lymphocytes during treatment would not 
be a major influence on the comparison of the cytogenetic and model doses.  
 
Despite the limitations and uncertainties of the physical models which are large and difficult 
to quantify fully, such as no knowledge of the blood volume in specific organs, the 
relationship between the cytogenetic and the model doses, which are independent of each 
other, is very promising, especially for EDD2, as shown in Figure 1. This implies that despite 
the models crude nature they may be useful. Both physical models have the capacity to be 
individualised further, which may mean the uncertainties reduce and this initial success will 
allow further development to take place; for example to take account of lymph nodes in the 
radiation field. The comparison of cytogenetic and model doses reveals an apparent 
sensitivity to the choice of model however this may be related to the small sample size (20 
patients).  
 
PB dose estimation, termed the contaminated Poisson method, was first proposed for 
dicentric data in the late 1960s (12) and is still one of the standard methods recommended 
for biological dosimetry (1). More recently, it has been suggested that Bayesian statistical 
analysis may be more suitable for dicentric data (37). A new Bayesian zero-inflated Poisson 
finite mixture method for estimating PB exposure has been developed with test data from 
simulated PB irradiations, where unirradiated and ex vivo irradiated blood samples were 
mixed in different proportions (13). Cytogenetic data from the RTGene study has allowed 
the Bayesian zero-inflated Poisson finite mixture method to be used after in vivo irradiation 
and for a comparison of PB dose estimates calculated by this new approach and the 
standard contaminated Poisson technique. The Bayesian method has shown the distribution 
of the radiation-induced damage at a cellular level can be expressed in terms of a gradient 
exposure, but the number of irradiated fractions is lower than the number of RT 
procedures. In part this difference may be the result of the fractionated nature of the 
exposure, with a different sub-set of lymphocytes being irradiated during each fraction. 
However, the good agreement between the Bayesian and standard technique indicate this 
new method to calculate PB dose has the potential to provide additional information 
regarding dose estimates and irradiated fraction for biological dosimetry. In all situations 
where the DCA is used to estimate PB dose, the Bayesian method is more accurate when 
information about the priors is well documented. However, if cytogenetic triage dose 
assessment is used, for example during a mass casualty event, where the aim is to place 
patients into broad dose categories, the more complex Bayesian approach may not be 
necessary. It is applicable when information about the priors is good and can more 
accurately characterise the dose, fractions and uncertainty, as all of these are included in 
the outcome. 
 
In summary, the results from the RTGene study using a conventional biomarker, the DCA, 
indicate they can be used to validate future gene expression data. Comparisons between 
the cytogenetic dose estimates and 1) blood dosimetric models and 2) the new Bayesian 
method for gradient exposure are very encouraging. This will allow further development of 
the dosimetric models and demonstrates the new Bayesian method can be applied 
following in vivo ionizing radiation exposures. A lot more work is needed, but the next step 
will be further development and validation in a larger patient group. The RTGene partners 
will also explore the possibility of combining the cytogenetic, DNA damage and gene 
expression data to form a multi-assay panel of biomarkers to inform on individual radiation 
exposure and effects.  
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Legends for tables and figures: 
 
Table 1. Table showing the tumour type, the RT schedule and the RT prescribed doses, 
together with the 95% isodose volume for each patient. 
 
Table 2. Dicentric chromosome aberrations in samples taken prior to the final RT fraction. 
Cells = Number of peripheral blood lymphocytes scored; Dics = Number of dicentric 
chromosome aberrations identified; y = yield of dicentrics; var:mean = variance: mean ratio, 
an indication of departure from Poisson and thus partial body exposure (var:mean for 
Poisson = 1); SE = standard error of the measurement in the previous column. In all the pre 
RT samples no cell contained more than 1 dicentric, thus the var:mean = 1.0 in all cases. 
 
Table 3. Dose following the penultimate fraction for each participant calculated using blood 
dosimetric models and the cytogenetic dose estimates calculated by standard and Bayesian 
methods (95% HPDCI = 95% Highest Posterior Density Credible Interval). 
 
Figure 1. Dose following the penultimate fraction to blood during RT calculated using 
models 1 (EDD1) and 2 (EDD2) and cytogenetic doses to the WB and PB, calculated using the 
standard contaminated Poisson methodology to separate exposed and unexposed fractions 
in PB exposures. 
 
Table 4. Table showing GLM ANOVA comparisons that revealed RT treatment for some 
cancer types resulted in either significantly lower (*) or higher (†) WB or PB cytogenetic 
doses. 
REFERENCES 
 
1. International Atomic Energy Agency. Cytogenetic Dosimetry: Applications in 
preparedness for and response to radiation emergencies. Vienna, Austria: IAEA; 2011. 
 
2. Kulka U, Abend M, Ainsbury E, Badie C, Barquinero JF, Barrios L, et al. RENEB – running 
the European Network of biological dosimetry and physical retrospective dosimetry. Int J 
Radiat Biol 2017; 93(1):2-14.  
 
3. Kabacik S, Mackay A, Tamber N, Manning G, Finnon P, Paillier F, et al. Gene expression 
following ionising radiation: identification of biomarkers for dose estimation and 
prediction of individual response. Int J Radiat Biol 2011; 87(2):115-29.  
 
4. Kabacik S, Ortega-Molina A, Efeyan A, Finnon P, Bouffler S, Serrano M, et al.  A minimally 
invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell 
Cycle 2011; 10(7):1152-61.  
 
5. Manning G, Kabacik S, Finnon P, Bouffler S, Badie C.  High and low dose responses of 
transcriptional biomarkers in ex vivo X-irradiated human blood. Int J Radiat Biol 2013; 
89(7):512-22.  
 
6. Kabacik S, Manning G, Raffy C, Bouffler S, Badie C. Time, dose and ataxia telangiectasia 
mutated (ATM) status dependency of coding and noncoding RNA expression after 
ionizing radiation exposure. Radiat Res 2015; 183(3):325-37.  
7. Manning G, Kabacik S, Finnon P, Paillier F, Bouffler S, Badie C. Assessing a new gene 
expression analysis technique for radiation biodosimetry applications. Radiat Meas 
2011; 46(9):1014-18.  
 
8. Manning G, Tichý A, Sirák I, Badie C. Radiotherapy-associated long-term modification of 
expression of the inflammatory biomarker genes ARG1, BCL2L1 and MYC. Front Immunol 
2017; 8:412.  
 
9. O’Brien G, Cruz-Garcia L, Majewski M, Grepl J, Abend M, Port M, et al.  FDXR is a 
biomarker of radiation exposure in vivo. Sci Rep 2018; 8:684.  
 
10. International Organization for Standardization. ISO 19238: radiation protection – 
performance criteria for service laboratories performing biological dosimetry by 
cytogenetics. Geneva, Suisse: ISO; 2014. 
 
11. International Atomic Energy Agency. Technical Report Series 430: Commissioning and 
quality assurance of computerized planning systems for radiation treatment of cancer. 
Vienna, Austria: IAEA; 2004. 
 
12. Dolphin GW. Biological dosimetry with particular reference to chromosome aberration 
analysis. A review of methods. Handling of Radiation Accidents. Proc Int Symp Vienna 
1969; IAEA, Vienna. 
13. Higueras M, Puig P, Ainsbury EA, Vinnikov VA, Rothkamm, K. A new Bayesian model 
applied to cytogenetic partial body irradiation estimation. Radiat Prot Dosim 2016; 
168:330-36.  
 
14. Ainsbury E, Lloyd D. Dose estimation software for radiation biodosimetry. Health Phys 
2010; 98(2):290-95.  
 
15. Lloyd DC, Purrott RJ, Dolphin GW, Bolton D, Edwards AA, Corp MJ. The relationship 
between chromosome aberrations and low LET radiation dose in human lymphocytes. 
Int J Radiat Biol 1975; 28:75-90. 
 
16. Pernot E, Hall J, Baatout S, Benotmane MA, Blanchardon E, Bouffler S, et al. Ionizing 
radiation biomarkers for potential use in epidemiological studies. Mut Res 2012; 
751:258-86.  
 
17. Sotnik NV, Azizova TV, Darroudi F, Ainsbury EA, Moquet JE, Fomina J. Verification by the 
FISH translocation assay of historic doses to Mayak workers from external gamma 
radiation. Radiat Environ Biophys 2015; 54:445-51.  
 
18. Hall J, Jeggo P, West C,  Gomalka M, Quintens R, Badie C, et al. Ionizing radiation 
biomarkers in epidemiological studies – An update.   Mut Res Reviews 2017; 771:59-84.  
 
 
19. Kerns SL, Dorling L, Fachal L, Bentzen S, Pharoah PDP, Barnes DR, et al. Meta-analysis of 
genome wide association studies identifies genetic markers of late toxicity following 
radiotherapy for prostate cancer. EBioMedicine 2016; 10:150-63.  
 
20. Andreassen CN, Rosenstei B, Kerns S, Ostrer H, De Ruysscher D, Cesaretti J, et al. 
Individual patient data meta-analysis shows a significant association between 
ATMrs1801516 SNP and toxicity after radiotherapy in 5,456 breast and prostate cancer 
patients. Radiother Oncol 2016; 121(3):431-39.  
 
21. Yang L, Taylor J, Eustace A, Irlam JJ, Denley H, Hoskin PJ, et al. A gene signature for 
selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer 
patients. Clin Cancer Res 2017; 23(16):4761-68.  
 
22. Borgmann K, Roper B, El-Awady RA, Brackrock S, Bigalke M, Dörk T, at al. Indicators of 
late normal tissue responses after radiotherapy for head and neck cancer: fibroblasts, 
lymphocytes, genetics, DNA repair and chromosome aberrations. Radiother Oncol 2002; 
64:141-52.  
 
23. Chua ML, Somaiah N, A’Hern R, Davies S, Gothard L, Yarnold J, et al. Residual DNA and 
chromosomal damage in ex vivo irradiated blood lymphocytes correlated with normal 
tissue response to breast radiotherapy. Radiother Oncol 2011; 99(3):362-66.  
 
24. Beaton LA, Marro L, Samiee S, Malone S, Grimes S, Malone K, et al. Investigating 
chromosome damage using fluorescent in situ hybridization to identify biomarkers of 
radiosensitivity in prostate cancer patients. Int J Radiat Biol 2013; 89(12):1087-93. 
 
25. Badie C, Dziwura S, Raffy C, Tsigani T, Alsbeih G, Moody J, et al. Aberrant CDKN1A 
transcriptional response associates with abnormal sensitivity to radiation treatment. Br J 
Cancer 2008; 98(11):1845-51.  
 
26. Mayer C, Popanda O, Greve B, Fritz E, Illig T, Eckardt-Schupp F, et al. A radiation-induced 
gene expression signature as a tool to predict acute radiotherapy-induced adverse side 
effects. Cancer Lett 2011; 302(1):20-28.  
 
27. Finnon P, Kabacik S, MacKay A, Raffy C, A’Hern R, Owen R, et al. Correlation of in vitro 
lymphocyte radiosensitivity and gene expression with late normal tissue reactions 
following curative radiotherapy for breast cancer. Radiother Oncol 2012; 105(3):329-36. 
 
28. Paul S, Amundson SA. Development of gene expression signatures for practical radiation 
biodosimetry. Int J Radiat Oncol Biol Phys 2008; 71(4):1236-44.  
 
29. Badie C, Kabacik S, Balagurunathan Y, Bernard N, Brengues M, Faggioni G, et al. 
Laboratory intercomparison of gene expression assays. Radiat Res 2013; 180(2):138-48.  
 
30. Ricoul M, Gnana-Sekaran T, Piqueret-Stephan L, Sabatier L. Cytogenetics for biological 
dosimetry. Methods in Molecular Biology 2017; 1541:189-208.  
 31. Yovino S, Kleinberg L, Grossman SA, Narayanan, Ford E. The etiology of treatment-
related lymphopenia in patients with malignant gliomas: Modeling radiation dose to 
circulating lymphocytes explains clinical observations and suggests methods of 
modifying the impact of radiation on immune cells. Cancer Invest 2013; 31(2):140-44. 
 
32. Vyas RC, Darroudi F, Natarajan AT. Radiation-induced chromosomal breakage and 
rejoining in interphase-metaphase chromosomes of human lymphocytes. Mut Res 1991; 
249:29-35. 
 
33. McLean AR, Mitchie CA. In vivo estimates of division and death rates of human T 
lymphocytes. Proc Natl Acad Sci USA 1995; 92:3707-11. 
 
34. Lucas JN, Hill FS, Burk CE, Cox AB Straume T. Stability of the translocation frequency 
following whole-body irradiation measured in rhesus monkeys. Int J Radiat Biol 1996; 
70(3):309-18. 
 
35. Chung HW, Kim SY, Sohn EH Ha SW. Analysis of chromosome aberrations in nuclear-
power-plant-workers considering the lifetime of lymphocytes. Int J Radiat Biol 2000; 
76:923-27. 
 
36. Edwards AA, Szłuińska M, Lloyd DC. Reconstruction of doses from ionising radiation 
using fluorescence in situ hybridization techniques. Br J Radiol 2007; 80:S63-7. 
 
37. Ainsbury EA, Vinnikov VA, Puig P, Higueras M, Maznyk NA, Lloyd DC, et al. Review of 
Bayesian statistical analysis methods for cytogenetic radiation biodosimetry, with a 
practical example. Radiat Prot Dosim 2014; 162(3):185-96.  
 
 
 
 
 
 
 
